Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by gericon Dec 26, 2013 12:07pm
243 Views
Post# 22038574

RE:RE:RE:Australian Trial

RE:RE:RE:Australian TrialThe unmotivated will always flock to a pill to solve their problems (ie. Lipitor).  The vast majority of Type 2 DM is related to lifestyle choices.  Ergo to prevent diabetes or treat pre-diabetes, the preferred treatment would be to change the diet and exercise.  It's the same with heart disease.  The diets laden with high fat processed food and refined sugars eaten in supersize quantities are the culprit.  This over eating of poor quality foods leads to overweight and obesity and the resultant chronic diseases.  The best treatment scenario is to deal with the cause, not try to treat the result.

I doubt that this latest trial will amount to anything.  Twenty patients with all the variables to consider, is too small.  Just another carrot to dangle.


Bullboard Posts